New immunosuppressants in pediatric solid organ transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 5, 2012, Pages 503-508

  Marks, Stephen D ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

children; chronic allograft damage; immunosuppression; outcomes; transplantation

Indexed keywords

BELATACEPT; BORTEZOMIB; CYCLOSPORIN A; ECULIZUMAB; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; MANITIMUS; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; SOTRASTAURIN; TACROLIMUS; TGN 1412; THYMOCYTE ANTIBODY; TOFACITINIB;

B LYMPHOCYTE; CHILD; DRUG MECHANISM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; ORGAN TRANSPLANTATION; PLASMA CELL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUBERCULOSIS;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 84866366554     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835741cd     Document Type: Review

References (48)

1. Benden C, Dipchand AI, Danziger-Isakov LA, et al. Pediatric transplantation: ten years on. Pediatr Transplant 2009; 13:272-277.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715-2729. (Pubitemid 39665325)
3. Sinha R, Saad A, Marks SD. Prevalence and complications of chronic kidney disease in paediatric renal transplantation: a K/DOQI perspective. Nephrol Dial Transplant 2010; 25:1313-1320.
4. Benden C, Kansra S, Ridout DA, et al. Chronic kidney disease in children following lung and heart-lung transplantation. Pediatr Transplant 2009; 13:104-110.
5. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes costimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15:746-749.
6. Krischock L, Marks SD. Induction therapy: why, when, and which agent? Pediatr Transplant 2010; 14:298-313.
7. Li L, Weintraub L, Concepcion W, et al. Potential influence of tacrolimus and steroid avoidance on early graft function in pediatric renal transplantation. Pediatr Transplant 2008; 12:701-707.
8. Li L, Chang A, Naesens M, et al. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant 2009; 9:1362-1372.
9. Marks SD, Trompeter RS. Steroid preservation: the rationale for continued prescribing. Pediatr Nephrol 2006; 21:305-307. (Pubitemid 43280341)
10. Sarwal M. Steroid elimination is coming of age. Pediatr Nephrol 2006; 21:2-4. (Pubitemid 43040187)
11. Krischock L, Gullett A, Bockenhauer D, et al. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection. Pediatr Transplant 2009; 13:475-481.
12. Sharif A, Shabir S, Chand S, et al. Meta-analysis of calcineurin- inhibitorsparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22:2107-2118.
13. Vincenti F. Are calcineurin inhibitors-free regimens ready for prime time? Kidney Int 2012. doi: 10.1038/ki.2012.194. [Epub ahead of print].
14. Busque S, Cantarovich M, Mulgaonkar S, et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant 2011; 11:2675-2684.
15. Sinha R, Tse Y, Marks SD. Conversion to monotherapy maintenance immunosuppression in pediatric renal transplant recipients: a single center experience. Pediatr Transplant 2011; 15:119-120.
16. Zonta S, Alessiani M, Vigano J, et al. Prolonged survival with FK778 (malononitrilamide) monotherapy after small bowel transplantation: a large animal study. Transplant Proc 2007; 39:2021-2023. (Pubitemid 47198811)
17. Guasch A, Roy-Chaudhury P, Woodle ES, et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation 2010; 90:891-897.
18. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028. (Pubitemid 44343545)
19. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5:686-693. (Pubitemid 29289433)
20. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belataceptbased, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11:66-76.
21. Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90:1528-1535.
22. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12:630-639.
23. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91:976-983.
24. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210-217.
25. Lee CF, Eldeen FZ, Chan KM, et al. Bortezomib is effective to treat acute humoral rejection after liver transplantation. Transplant Proc 2012; 44:529-531.
26. Sureshkumar KK, Hussain SM, Marcus RJ, et al. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. Clin Nephrol 2012; 77:246-253.
27. Guthoff M, Schmid-Horch B, Weisel KC, et al. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012; 26:171-175.
28. Lonze BE, Dagher NN, Simpkins CE, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010; 10:2154-2160.
29. Krid S, Roumenina L, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012; 12:1938-1944.
30. Nester C, Stewart Z, Myers D, et al. Preemptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6:1488-1494.
31. Weitz M, Amon O, Bassler D, et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26:1325-1329.
32. McCaughan JA, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12:1046-1051.
33. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
34. Eleftheriou D, Melo M, Marks SD, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 2009; 48:978-986.
35. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52:3168-3174. (Pubitemid 41447099)
36. Prytula A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010; 25:461-468.
37. Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91:853-857.
38. Tyden G, Kumlien G, Berg UB. ABO-incompatible kidney transplantation in children. Pediatr Transplant 2011; 15:502-504.
39. Jin MK, Cho JH, Kwon O, et al. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc 2012; 44:200-203.
40. Jordan SC, Reinsmoen N, Lai CH, et al. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation. Transplant Proc 2012; 44:60-61.
41. Friman S, Arns W, Nashan B, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 2011; 11:1444-1455.
42. Kovarik JM, Steiger JU, Grinyo JM, et al. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. Transplantation 2011; 91:317-322.
43. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9:1936-1945.
44. Quaedackers ME, Mol W, Korevaar SS, et al. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 2009; 88:1002-1009.
45. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009; 145:937-942.
46. Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65:546-551.
47. Turgeon NA, Avila JG, Cano JA, et al. Experience with a novel efalizumabbased immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant 2010; 10:2082-2091.
48. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7:1770-1777. (Pubitemid 46905435)